TITLE

Allergan launches antihistamine drop

PUB. DATE
February 2011
SOURCE
Ocular Surgery News;2/25/2011, Vol. 29 Issue 4, p27
SOURCE TYPE
Academic Journal
DOC. TYPE
Product Review
ABSTRACT
The article discusses the launch of the alcaftadine ophthalmic solution from Allergan.
ACCESSION #
86439062

 

Related Articles

  • Industry Pipeline.  // Ocular Surgery News;5/25/2013, Vol. 31 Issue 10, p48 

    The article presents news briefs related to the ophthalmic industry around the world. The U.S. Food and Drug Administration (FDA) has approved the Tecnis toric intraocular lens from Abbott for cataract patients with pre-existing corneal astigmatism. It has released the 510(k) clearance for the...

  • Bepotastine Ophthalmic.  // AHFS Consumer Medication Information;Feb2018, p1 

    Bepotastine ophthalmic is used to treat itching of the eyes caused by allergic conjunctivitis (a condition in which the eyes become itchy, swollen, red, and teary when they are exposed to certain substances in the air). Bepotastine is in a class of medications called antihistamines. It works by...

  • The Right Fix.  // Good Housekeeping;Sep2010, Vol. 251 Issue 3, p65 

    The article evaluates allergy remedies including the allergy-control eyedrops Zaditor, the nasal decongestant spray Neo-Synephrine and the oral antihistamine Claritin.

  • Regeneron, Bayer Healthcare launch phase 3 trial with Singapore Eye Research Institute. OSN Staff Writers // Ocular Surgery News;2/25/2011, Vol. 29 Issue 4, p30 

    The article reports that Regeneron and Bayer HealthCare, in partnership with Singapore Eye Research Institute (SERI) have launched the phase 3 clinical trial on vascular endothelial growth factor (VEGF) Trap-Eye in patients with myopic choroidal neovascularization.

  • Alcaftadine the latest allergy option. Greiner, Jack V. // Optometry Times;Feb2011, Vol. 3 Issue 2, p27 

    The article discusses the efficacy of alcaftadine as a treatment for ocular allergy. It describes alcaftadine ophthalmic solution 0.25% as a topical antihistamine medication that protects the zonula ocludens-1 and E-cadherin protein components of the conjuctival epithelial barrier. The article...

  • Epinastine Ophthalmic.  // AHFS Consumer Medication Information;Feb2018, p1 

    Ophthalmic epinastine is used to prevent itching of the eyes caused by allergic conjunctivitis (a condition in which the eyes become itchy, swollen, red, and teary when they are exposed to certain substances in the air). Epinastine is in a class of medications called antihistamines. It works by...

  • Industry Pipeline.  // Ocular Surgery News;9/25/2011, Vol. 29 Issue 18, p34 

    This section offers news briefs concerning the U.S. ophthalmic industry including the marketing clearance received by OcuSense from the U.S. Food and Drug Administration (FDA) involving its TearLab Osmolarity System and Test Card, the start of the phase 3 clinical study of investigational drug...

  • Bepotastine yields lasting relief. Krader, Cheryl Guttman; O'Brien, Terrence P. // Optometry Times;Feb2011, Vol. 3 Issue 2, p32 

    The article offers information on the efficacy of bepotastine for reducing ocular itching in patients with allergic conjunctivitis. It presents the findings of clinical studies using the conjunctival allergen challenge (CAC) model wherein patients were randomly treated with bepotastine besilate...

  • Topical agent offers rapid, sustained relief of itching from allergic conjunctivitis. Hasson, Matt // Ocular Surgery News;10/25/2011, Vol. 29 Issue 20, p54 

    The article focuses on the use of the Lastacaft eye drop for the treatment of itching caused by allergic conjunctivitis. Rajesh K. Rajpal, an ophthalmologist, states that the eye drop is well-tolerated and that most of his patients are comfortable with it. Lastacaft is said to have no...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics